Clinical Laserthermia Systems AB OMXSTO:CLS_B:
Q4 NET SALES SEK 830 THOUSAND
Q4 OPERATING LOSS SEK 10,615,000
CONTINUES TO MAINTAIN COMMUNICATED TARGETS FOR 2026
Clinical Laserthermia Systems Says Continues To Maintain Targets For 2026
Clinical Laserthermia Systems AB on 6ix
Earlier from Clinical Laserthermia Systems
- CLS Initiates Recruitment Process For Permanent Chief Financial Officer
- Clinical Laserthermia Systems Q3 Revenue SEK 2.8 Mln
- CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results
- Clinical Laserthermia Systems AB: Quarterly Trading Report 2025 Q3
- CLS Raises SEK 20.9 Mln Through Full Subscription Of Warrants
Later from Clinical Laserthermia Systems
- CLS Receives Order Worth SEK 23 Mln For Prism Business
- Sweden's CLS Q1 sales fall 72% after partner talks
- CLS Enters Research Agreement With U.S. National Cancer Institute
Follow Clinical Laserthermia Systems into a list and get an email when it puts out news.
Follow Clinical Laserthermia Systems